The Valley Desk

ArticleUrologic oncologyPublished

Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Temple Health. Affiliation source

Publication record

Type
Article
Venue
Urologic oncology
Published
Subject terms
Humans; Neoplasm Invasiveness; BCG Vaccine; Adjuvants, Immunologic; Administration, Intravesical; Aged; Medicare; United States; Urinary Bladder Neoplasms; Docetaxel; Gemcitabine; Non-Muscle Invasive Bladder Neoplasms
PubMed ID
37127478
Added to directory
Source checked

Report a correction or request removal